Plerixafor
Plerixafor is a CXCR4 receptor antagonist used to mobilize hematopoietic stem cells from bone marrow into the peripheral blood. It is indicated for use in combination with granulocyte colony-stimulating factor (G-CSF) to facilitate stem cell collection in patients with lymphoma or multiple myeloma who are undergoing autologous stem cell transplantation.
A stem cell mobilizing agent that blocks CXCR4 receptors to release stem cells into the bloodstream for collection and transplantation in blood cancer patients.
Key facts at a glance
- ATC
- L03AX16
- RxNorm
- 733003
- Generic
- Plerixafor
- Class
- atc-l03
- Brands
- Mozobil
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks; discuss with healthcare provider
regular fetal monitoring and ultrasound assessments
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid if possible
avoid use during pregnancy unless clearly necessary
regular fetal monitoring and uterine activity monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingdiscontinue breastfeeding or avoid drug
unknown if plerixafor is excreted in human milk; discontinue breastfeeding or avoid use
monitor infant for adverse effects
pediatric_age
children 2 to 17 yearsweight-based dosing required
approved for patients 2 years and older; use with G-CSF for stem cell mobilization; monitor for injection site reactions
monitor CBC and stem cell mobilization efficacy
Use with caution and monitor for adverse effects.
geriatric
elderly 65 years and olderno specific dose adjustment; monitor renal function
no clinically significant differences in efficacy or safety observed; assess renal function before dosing
monitor renal function and for adverse reactions
Use with caution and monitor for adverse effects.
renal_impairment
severe renal impairment clcr less than 30 ml minreduce dose by one-third; 0.16 mg/kg instead of 0.24 mg/kg
reduce dose to 0.16 mg/kg; monitor renal function; use with caution
monitor renal function before and during treatment; assess for adverse effects
Use with caution and monitor for adverse effects.
renal_impairment
moderate renal impairment clcr 30 50 ml minconsider dose reduction to 0.16 mg/kg
consider dose reduction; monitor renal function closely
monitor renal function before and during treatment
Use with caution and monitor for adverse effects.
hepatic_impairment
moderate to severe hepatic impairmentno specific dose recommendation; use with caution
limited clinical data; use only if benefits outweigh risks
monitor liver function tests
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Pharmacological classification of Plerixafor
FDA approval year
FDA regulatory approval information
Primary indication
Therapeutic indication in combination with G-CSF
Mechanism of action
Pharmacodynamic mechanism of action
Plerixafor is used with G-CSF to mobilize hematopoietic stem cells from bone marrow to peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma, Hodgkin's lymphoma, and multiple myeloma.
Plerixafor reversibly blocks the CXCR4 chemokine receptor, preventing SDF-1α (stromal cell-derived factor-1α) from binding. This disrupts the retention signal that anchors stem cells in the bone marrow, causing their release into the peripheral bloodstream where they can be collected.
Administered as a subcutaneous injection, typically 24 hours after G-CSF dosing. Common side effects include injection site reactions, gastrointestinal symptoms, and transient decreases in blood counts. Should only be used under specialist supervision in transplant centers. Not indicated for long-term use.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy